Transcatheter Aortic Valve Replacement Market Report 2026

Transcatheter Aortic Valve Replacement Market Overview

• Transcatheter Aortic Valve Replacement market size has reached to $5.87 billion in 2025 • Expected to grow to $11.44 billion in 2030 at a compound annual growth rate (CAGR) of 14.3% • Growth Driver: Rising Prevalence Of Aortic Stenosis Propels Growth In The Transcatheter Aortic Valve Replacement Market • Market Trend: Innovations In Valve Tissue Engineering Technology Improve Durability And Long-Term Outcomes In Transcatheter Aortic Valve Replacement • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Transcatheter Aortic Valve Replacement Market?

Transcatheter aortic valve replacement (TAVR), also known as transcatheter aortic valve implantation (TAVI), is a minimally invasive medical procedure used to replace a diseased or malfunctioning aortic valve in the heart. It can be performed on adults who are not in good enough health to undergo standard valve surgery. The main products of transcatheter aortic valve replacement are self-expandable transcatheter aortic valves, balloon-expandable transcatheter aortic valves, and mechanically expanded transcatheter aortic valves. Self-expandable transcatheter aortic valves are medical devices used in a minimally invasive procedure called transcatheter aortic valve replacement (TAVR) or transcatheter aortic valve implantation (TAVI). These are made of valve frame material and valve leaflet material. Transfemoral implantation, transapical implantation, and transaortic implantation procedures can be done for aortic stenosis, aortic regurgitation, and others. These are performed by hospitals, independent cardiac catheterization labs, ambulatory surgical centers, and others.

What Is The Transcatheter Aortic Valve Replacement Market Growth Forecast?

The transcatheter aortic valve replacement market size is expected to see rapid growth in the next few years. It will grow to $11.44 billion in 2030 at a compound annual growth rate (CAGR) of 14.3%. The growth in the forecast period can be attributed to increasing adoption of TAVR in intermediate-risk patients, rising demand for durable valve solutions, expansion of structural heart programs, growing integration of advanced imaging technologies, increasing focus on outpatient cardiac procedures. Major trends in the forecast period include increasing adoption of minimally invasive valve replacement procedures, rising use of self-expandable valve technologies, growing expansion into lower-risk patient groups, enhanced focus on procedural accuracy and imaging guidance, expansion of transfemoral access techniques.

Global Transcatheter Aortic Valve Replacement Market Segmentation

1) By Product: Self-Expandable Transcatheter Aortic Valves, Balloon-Expandable Transcatheter Aortic Valves, Mechanically Expanded Transcatheter Aortic Valves 2) By Material: Valve Frame Material, Valve Leaflet Material 3) By Procedure: Transfemoral Implantation, Transapical Implantation, Transaortic Implantation 4) By Application: Aortic Stenosis, Aortic Regurgitation, Other Applications Subsegments: 1) By Self-Expandable Transcatheter Aortic Valves: Nitinol Frame Self-Expandable Valves, Polyester and Polyurethane Coated Valves 2) By Balloon-Expandable Transcatheter Aortic Valves: Balloon-Expandable Valves with Stent Design, Resilient Balloon-Expandable Valves 3) By Mechanically Expanded Transcatheter Aortic Valves: Manually Expanded Valves, Mechanically Operated Valve Systems

What Is The Driver Of The Transcatheter Aortic Valve Replacement Market?

The increase in the prevalence of aortic stenosis is one of the driving factors for the transcatheter aortic valve replacement market going forward. Aortic stenosis is a medical condition that refers to the narrowing of the aortic valve in the heart. It can be treated with transcatheter aortic valve replacement (TAVR), a less invasive alternative to surgical aortic valve replacement (SAVR) that aids in restoring blood flow and reducing the signs and symptoms of aortic valve stenosis. For instance, in May 2024, according to a data published by the American Heart Association, a US-based nonprofit organization, over 12% of older Americans are affected by aortic stenosis, a condition frequently seen in individuals over 65. If left untreated, it can result in heart failure and potentially be fatal. Furthermore, in March 2023, according to the report published by the National Institute for Health and Care Excellence (NICE), a UK-based public organization, nearly 1.5% of people over 55 in the UK, or around 300,000, live with severe aortic stenosis, with just under 200,000 having symptomatic disease requiring treatment, contributing to over 380,000 people on cardiac waiting lists by March 2023. Therefore, the increase in the prevalence of aortic stenosis is driving the transcatheter aortic valve replacement industry

Key Players In The Global Transcatheter Aortic Valve Replacement Market

Major companies operating in the transcatheter aortic valve replacement market are Abbott Laboratories Inc., Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, LivaNova PLC, Meril Life Sciences Pvt. Ltd., Venus MedTech HangZhou Inc, Braile Biomedica, Peijia Medical Limited, Direct Flow Medical Inc., Transcatheter Technologies GmbH, Symetis SA, JenaValve Technology Inc., Micro Interventional Devices Inc., Xeltis BV, Tendyne Holdings Inc., MVRx Inc., Keystone Heart Ltd., Colibri Heart Valve LLC, HighLife SAS, Neovasc Inc., Aegis Surgical Limited, Foldax Inc., MValve Technologies Ltd., NaviGate Cardiac Structures Inc.

Global Transcatheter Aortic Valve Replacement Market Trends and Insights

Major companies operating in the transcatheter aortic valve replacement (TAVR) market are focusing on developing advanced solutions, such as structural valve deterioration monitoring, to enhance long-term valve durability, improve patient outcomes, and reduce the need for repeat procedures. Structural valve deterioration monitoring refers to the ongoing assessment of bioprosthetic heart valves using imaging, diagnostic tools, and clinical evaluation to detect early signs of leaflet damage, calcification, or functional decline. For instance, in May 2024, Edwards Lifesciences, a US-based medical technology company, introduced the Sapien 3 Ultra Resilia valve in Europe, becoming the only TAVR system equipped with the company’s Resilia tissue technology. This platform incorporates bovine pericardial tissue treated with anti-calcification methods designed to block calcium buildup and maintain valve function over time. By leveraging this tissue-preservation technology, Edwards Lifesciences seeks to enhance valve durability and support improved long-term clinical results for patients undergoing transcatheter aortic valve replacement.

What Are Latest Mergers And Acquisitions In The Transcatheter Aortic Valve Replacement Market?

In August 2024, Edwards Lifesciences, a US-based provider of structural heart therapies and transcatheter valve replacement technologies, acquired JC Medical for an undisclosed amount. With this acquisition, Edwards aims to expand its transcatheter aortic valve replacement portfolio by adding advanced solutions for native aortic regurgitation and strengthening its position in next-generation structural heart interventions. JC Medical is a US-based provider of transcatheter aortic valve replacement devices.

Regional Outlook

North America was the largest region in the transcatheter aortic valve replacement market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Transcatheter Aortic Valve Replacement Market?

The transcatheter aortic valve replacement market consists of revenues earned by entities by providing services such as repairing the valve without removing the old damaged valve and placement of a heart valve into the body. The market value includes the value of related goods sold by the service provider or included within the service offering. The transcatheter aortic valve replacement market also includes sales of stainless-steel stent, skirt and bovine pericardium leaflets, which are used in providing transcatheter aortic valve replacement services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.